advertisement
Zhang M 10
Showing records 1 to 10 | Display all abstracts from Zhang M100510 Inhibition of p66Shc attenuates retinal ischemia-reperfusion injury-induced damage by activating the akt pathway
Zhang M
Experimental Eye Research 2022; 220: 109082
100826 Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
Zhou B; Shi Y
Frontiers in endocrinology 2022; 13: 907340
100510 Inhibition of p66Shc attenuates retinal ischemia-reperfusion injury-induced damage by activating the akt pathway
Yang J
Experimental Eye Research 2022; 220: 109082
100826 Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
Fu R
Frontiers in endocrinology 2022; 13: 907340
100510 Inhibition of p66Shc attenuates retinal ischemia-reperfusion injury-induced damage by activating the akt pathway
Ji K
Experimental Eye Research 2022; 220: 109082
100826 Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
Ni H
Frontiers in endocrinology 2022; 13: 907340
100510 Inhibition of p66Shc attenuates retinal ischemia-reperfusion injury-induced damage by activating the akt pathway
He X; He T
Experimental Eye Research 2022; 220: 109082
100826 Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
Gu L
Frontiers in endocrinology 2022; 13: 907340
100510 Inhibition of p66Shc attenuates retinal ischemia-reperfusion injury-induced damage by activating the akt pathway
Xing Y
Experimental Eye Research 2022; 220: 109082
100826 Relationship Between SGLT-2i and Ocular Diseases in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials
Si Y; Zhang M; Jiang K; Shen J; Li X; Sun X
Frontiers in endocrinology 2022; 13: 907340
